 |
인쇄하기
취소
|
Green Cross to conduct clinical trial of anti-anemic agent
Green Cross Corporation said Tuesday it will carry out Phase 1 trial for GC1113, a generic version of Amgen’s Epogen.
Co-developed by Genexine, GC1113 is a recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native huma...
Co-developed by Genexine, GC1113 is a recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native huma...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.